DETECTING THE UNDETECTABLE

Reliably detecting immuno-modulating proteins in serum and plasma from normal individuals has historically been impossible due to the lack of sensitivity of conventional immunoassays. Quanterix and Rules-Based Medicine, a Q² Solutions Company (formerly Myriad RBM) are working together to change this paradigm via ultrasensitive, high quality immunoassay services that offer drug developers an unparalleled approach to clinical research.

Quanterix, the developer of single molecule arrays (Simoa) technology, will describe the use of Simoa for the detection of proteins at very low concentrations, capable of providing a 1000-fold improvement in sensitivity to proteins over conventional assays. We will review the scientific principles that allow counting individual protein molecules and we will demonstrate how the Simoa technology can be used to obtain remarkable improvements in sensitivity, which has enabled significant breakthroughs in several therapy areas.

RBM, a leader in immunoassay testing services, will describe validated Simoa-based assay services and how carefully designed calibrators and controls ensure quality, precision and accuracy. Examples of how these reproducible assays, offered as a service in RBM’s CLIA certified lab, can measure proteins at the femtogram per mL level will be demonstrated by quantifying key immune modulating proteins, present at undetectable levels with conventional technology in serum and plasma, from normal and diseased subjects. In conclusion, we will show that the unprecedented sensitivity and reliability of these ultrasensitive immunoassay services have the potential to revolutionize clinical research in multiple therapeutic areas including immuno-oncology, autoimmune disorders, cardiovascular diseases and other research focusing on inflammatory processes.

Presenters

Dominic Eisinger, Ph.D., Vice President of Sales and Marketing, RBM

Dominic Eisinger, PhD, is a member of the business and scientific management team at RBM. Prior to joining RBM he was President of Multiplex Biosciences, a multiplex immunoassay development and manufacturing company he started. Dr. Eisinger has also held previous management positions in R&D related to multiplex immunoassay development, molecular biology and tumor vaccine antigen discovery. He has over 18 years industry experience in various scientific and commercialization roles and is a noted international authority on protein arrays. Dr. Eisinger has B.S. in biochemistry from Cornell University and a PhD in molecular biology from the University of Vermont prior to completing post-doctoral training at Dartmouth Medical School.

Mark Roskey, VP/GM, Applications and Reagents, Quanterix

Mark Roskey joined Quanterix in mid 2014 as the Vice President and General Manager of Applications and Reagents. Mark comes to Quanterix from PerkinElmer’s LST division where he was VP/GM of the America’s Sales and Service organization. Prior to PerkinElmer, Mark held senior level commercial and technical positions at Caliper Life Sciences which was acquired by PerkinElmer in 2011. Mark has more than 25 years of experience in the life science industry focusing on product R&D, applications development, strategic sales and marketing, and overall business management for complex biological solutions and automated instrument systems. Dr. Roskey has a Ph.D. in Microbiology from the University of Notre Dame and completed a postdoctoral fellowship in Molecular Immunobiology at the Harvard Medical School.